Oxford 2 July 2017; Celleron Therapeutics Limited, the UK based precision cancer medicines company, developing novel small molecule therapeutics, announced today that research on CXD101 its novel dual action HDAC inhibitor had been presented at the 3rd Shanghai International Forum for Lymphoid Malignancy, run by the Union for China Lymphoma Investigators, in Shanghai, China.
The meeting focused on the role and potential for new treatments in Lymphoma. Through its novel mode of action CXD101 has a key role in the epigenetics of gene replication. CXD101 has been shown to have potential in Lymphomas both alone and particularly in combination with checkpoint inhibitors, in addition to potential in solid tumours, including colorectal cancer (CRC) and hepatocellular carcinoma (HCC)
Professor Nick La Thangue, CEO of Celleron Therapeutics, reviewed the fundamental research into the regulation of acetylation in lymphomas, which has led to the development of CXD101 and recent results showing its unique immune-modulatory effects on tumour cells. Professor La Thangue also presented the clinical data from the Phase 1 programme with CXD101 showing compelling clinical efficacy as monotherapy and that the product is very well tolerated as oral therapy, as well as the clinical plans for the product. Phase 2 trials are planned to start in 2017.
Professor La Thangue said “We are very pleased to present CXD101 at this important meeting and to have the opportunity to discuss the novel research and the exciting clinical plans which could lead to significant benefit for patients with lymphomas”
About Celleron Therapeutics
Celleron Therapeutics, based on the Oxford Science Park, UK, is a drug development company focussed on precision medicine for cancer. It is a spin-out of Oxford University and has secured a number of exclusive licence agreements with pharmaceutical companies, including Astra Zeneca. Celleron’s precision medicine approach is supported by a companion diagnostic biomarker platform, which allows new drugs to be tailored to responsive tumours. Celleron has two Phase 2 clinical assets: CXD101 is a novel dual mechanism HDAC inhibitor which has unique immuno-modulatory effects in tumour cells, and CXD201 represents a new type of topoisomerase inhibitor.